DelRicht Research is proud to share that Dr. Ira Thorla of LA Dermatology Associates has been invited to participate as an author for an encore presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2025, taking place in Paris from September 17–20.

The abstract, titled “Efficacy and Safety of Ruxolitinib Cream Combined With NB-UVB Phototherapy for Treatment of Vitiligo”, was originally submitted to the 2024 Vitiligo International Symposium (VIS) and has garnered continued interest from the dermatology research community. Incyte, the study sponsor, has selected this work for encore submission, underscoring its clinical relevance and impact in advancing vitiligo treatment strategies.

Dr. Thorla’s contributions to this important research reflect DelRicht Research’s ongoing commitment to supporting innovative therapeutic approaches and improving outcomes for patients with chronic skin conditions.

We congratulate principal investigator Dr. Ira Thorla on this recognition and look forward to seeing this work showcased on an international stage.

Learn more about our dermatology research at DelRicht Research.